// Jie Zhang 1 , Hong-Ying Zhang 2 , Jia Li 1 , Xin-Yu Shao 3 and Chun-Xia Zhang 1 1 Department of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China 2 Department of Pathology and Forensic Medicine, College of Basic Medical Sciences, Dalian Medical University, Dalian 116044, China 3 Medical Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian 116000, China Correspondence to: Chun-Xia Zhang, email: qm1210@hotmail.com Keywords: colorectal cancer, neutrophils-to-lymphocytes ratio, platelet-to-lymphocytes ratio, platelet counts, prognosis Received: February 24, 2017 Accepted: May 05, 2017 Published: June 19, 2017 ABSTRACT Recently, several studies have reported that inflammatory response and elevated platelet counts may be associated with the poor prognosis of colorectal cancer. This meta-analysis was designed to analyze and evaluate the prognostic role of elevated preoperative or pretreatment neutrophils-to-lymphocytes ratio, platelet-to-lymphocytes ratio or platelet counts in patients with colorectal cancer. We searched PubMed, EMBASE, Cochrane Library and Web of Science to April, 2016. A total of 23 studies ( N = 11762 participants) were included for this meta-analysis. Elevated neutrophils-to-lymphocytes ratio have a close relationship with the poor Overall Survival of colorectal cancer with the pooled HR being 1.92 [95% CI 1.57–2.34; P < 0.00001]. This meta-analysis indicated that elevated neutrophils-to-lymphocytes ratio, platelet-to-lymphocytes ratio or platelet counts may be a cost-effective and noninvasive serum biomarker for poor prognosis for patients with colorectal cancer.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: